Popular Trials
NMDA Receptor Antagonist
Memantine for Cognitive Impairment in SLE
This trial is testing memantine, a drug that blocks certain brain receptors, in people with Systemic Lupus Erythematosus (SLE) who have a specific genetic variant. The goal is to see if memantine can safely and effectively reduce cognitive symptoms in these patients. Memantine is used to treat memory and thinking problems and has been investigated for similar issues in SLE patients.
Monoclonal Antibodies
PF-06823859 for Systemic Lupus Erythematosus
This trial is researching if a drug, PF-06823859, is safe and effective for adults with CLE or SLE and skin symptoms. 48 participants will receive active study medicine or placebo for 65 weeks of study.
Cell Therapy
Islet Cell Transplant for Type 1 Diabetes
This trial is testing if it's safe to transplant human islet cells to help control blood sugar in type 1 diabetes patients who have trouble controlling it. Early observations will also be made about if this treatment can help with hypoglycemia.
Behavioural Intervention
Antidepressant Treatment +1 More for Depression
This study will determine whether there are age-related differences in the body systems controlling sleep and stress hormone patterns. This study will also determine whether the differences in sleep and hormone patterns between depressed adolescents and adults are associated with differences in their response to antidepressant treatment.
Cell Therapy
Pancreatic Islets of Langerhans Cell Transplant for Type 1 Diabetes
This protocol will provide islet cell transplantation to two separate populations in need of a pancreas transplant: Group I: Islet Cell Transplantation in Type I Diabetics without Kidney Problems Group II: Islet Cell Transplantation in Type I Diabetics Who Have a Stable Functioning Kidney Transplant The targeted patients have very brittle diabetes or dangerous hypoglycemic unawareness and may benefit from transplantation over continuing insulin therapy, even though chronic immunosuppression is required. We believe that in these patients, the islet transplant procedure promises enough potential benefit to justify subjecting patients who have not previously had a transplant to the risk of immunosuppression. In patients who are already subject to the dangers of chronic immunosuppression for other reasons, i.e. to prevent rejection of a kidney allograft, the islet transplantation procedure itself is the principal additional risk and this risk should be minimal. In these patients (our Group II), the potential benefit from improved glycemic control is that it promises to slow or even reverse diabetic complications, such as vascular problems leading to kidney damage. It is this rationale that has made pancreas transplantation a widely accepted option in patients with renal failure, despite the risks associated with whole pancreas transplantation. Islet cell transplantation aims to provide a potentially lower risk procedure that has similar relief from diabetic complications.
Popular Filters
Trials for Obstructive Sleep Apnea Patients
1 for Obstructive Sleep Apnea
The purpose of this study is to define the mechanism(s) through which Obstructive Sleep Apnea/Hypopnea (OSAH) promotes abnormal metabolic processes which characterize the metabolic syndrome. The investigators hypothesize that the sleep fragmentation and intermittent sleep hypoxia which occur in OSAH patients promote oxidative stress and inflammation which in turn lead to insulin resistance, dyslipidemia, abnormal vascular reactivity and other processes which are consistent with the metabolic syndrome.
Procedure
Sleep Endoscopy for Obstructive Sleep Apnea
This trial is studying a new way to examine the upper airway in people with obstructive sleep apnea who are getting surgery for their sleep apnea. The study is finding out how well this new technique works and if it can help predict who will or will not respond to sleep apnea surgery.
Procedure
Coblation-tonsillotomy +1 More for Obstructive Sleep Apnea
Removal of the adenoid and tonsils, known as an adenotonsillectomy (AT) is one of the most frequently performed surgical procedures in North America. The two most prevalent indications for this procedure in children are recurrent bacterial tonsillitis and obstructive sleep apnea (OSA). OSA is a common childhood condition that is characterized by upper airway obstruction, disturbed sleep and disrupted normal respiratory gas exchange. In the majority of children with OSA, overgrowth of the adenoid and tonsils is the primary underlying aetiology, making tissue removal via AT the standard of care. The purpose of this study is to evaluate the effectiveness of two different surgical techniques, electrocautery-tonsillectomy and coblation-tonsillotomy, in the treatment of obstructive sleep apnea (OSA) in children.
Positive Airway Pressure
PAP therapy for Obstructive Sleep Apnea
Obstructive sleep apnea is a problem for a large number of children and can result in problems with thinking patterns, behaviors and sleep if left untreated. Little is known about how positive airway pressure (PAP) therapy might help children who need treatment for obstructive sleep apnea. We will investigate how PAP therapy might be able to improve thinking patterns, behavior and sleep problems in children with obstructive sleep apnea.
Trials for Systemic Lupus Erythematosus Patients
Cenerimod for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Phase 3 Trials
Cenerimod for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Anti-malarial drug
Stopping Hydroxychloroquine for Lupus
This trial is testing if older lupus patients can safely stop taking Hydroxychloroquine, a drug that reduces lupus symptoms but can harm the eyes over time. The study focuses on patients aged 60 and above who have stable disease. Researchers will monitor these patients for an extended period to see if their condition remains stable without the drug.
Trials With No Placebo
Behavioral Intervention
Chronic Disease Self-Management Program for Systemic Lupus Erythematosus
This trial examines if a health education program can improve health and reduce healthcare use in African American women with lupus. The program involves regular sessions that teach practical skills for managing health problems. Researchers want to see if this helps these women better manage their condition. This community-based education program is designed to help participants gain confidence and skills to better manage their chronic conditions; it has been implemented worldwide.
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
View More Related Trials
Frequently Asked Questions
Introduction to sle
What are the top hospitals conducting sle research?
When it comes to advancing the understanding and treatment of Systemic Lupus Erythematosus (SLE), several top hospitals are leading the way with their clinical trials. In Nashville, Vanderbilt University Medical Center is making strides with five ongoing SLE trials and a total of six completed trials since they began their first recorded trial in 2017. Moving north to Chicago, Northwestern University has been actively involved in this research field as well, currently conducting four active SLE trials alongside an impressive history of 14 completed studies dating back to their inaugural trial in 2002.
Meanwhile, the renowned Mayo Clinic located in Rochester also plays a significant role by contributing valuable insights through its four ongoing SLE trials and involvement in five prior investigations spanning from as early as 1995. Washington University School of Medicine situated in Saint Louis demonstrates dedication towards addressing SLE through three current clinical trials while adding depth to this commitment with six previous studies conducted since initiating their initial trial back in 2013.
Adding itself to this list is NYU Langone Health based out of New york City where researchers are currently engaging with three active clinical tests focusing on SLE; interestingly theirs marks a new era being traced back only two years ago from2023 when they first launched their pioneering investigation into these cases.
These hospitals serve as vital contributors toward fighting against systemic lupus erythematosus, a complex autoimmune condition that affects multiple organs and systems within the body. Through cutting-edge research and innovative clinical trials conducted at these institutions across different locations, patients affected by SLE can find hope for improved treatments and ultimately better quality of life. Their collective efforts symbolize progress toward unraveling the mysteries surrounding this challenging disease
Which are the best cities for sle clinical trials?
When it comes to clinical trials for systemic lupus erythematosus (SLE), several cities in the United States are at the forefront of research. New york, with its 20 active trials, explores treatments such as Hydroxychloroquine (HCQ) and Administration of CC-97540 among others. Following closely behind is Houston, Texas, with 19 ongoing studies focusing on interventions like Cenerimod 4 mg and ALPN-101. Chicago, Illinois also plays a significant role in SLE research with 14 active trials investigating treatments including Dupilumab and BIIB059 High Dose. These cities provide valuable opportunities for individuals seeking participation in cutting-edge SLE clinical trials that may lead to improved treatment options and better outcomes.
Which are the top treatments for sle being explored in clinical trials?
In the realm of systemic lupus erythematosus (SLE) clinical trials, one treatment has emerged as a frontrunner: Cenerimod 4 mg. This cutting-edge drug is currently being explored in two active SLE trials and marks its debut in 2018 with only one all-time SLE trial to date. With ongoing research and development, Cenerimod holds great promise for revolutionizing the treatment landscape for SLE patients worldwide.
What are the most recent clinical trials for sle?
Recent clinical trials offer hope for individuals living with systemic lupus erythematosus (SLE), as innovative treatments and interventions are being explored. One notable trial is investigating the effectiveness of dupilumab, a medication that shows promise in managing SLE symptoms. Additionally, another study focuses on the administration of CC-97540, aiming to identify its potential benefits in treating this complex autoimmune disease. Furthermore, a Phase 2 trial referred to as Group 1 aims to evaluate an experimental intervention specifically designed for SLE patients. Another promising avenue lies in cenerimod 4 mg, which is undergoing Phase 3 testing for its efficacy against SLE symptoms. Lastly, researchers are exploring the impact of health communication messages on improving outcomes for individuals with SLE through a combined Phase 1 and Phase 2 study. With these diverse investigations underway, advancements towards better management and treatment options for SLE appear within reach.
What sle clinical trials were recently completed?
Recently, several clinical trials investigating potential treatments for systemic lupus erythematosus (SLE) have been successfully completed. Notably, in February 2022, Daiichi Sankyo concluded a trial studying DS-7011a's effectiveness. Earlier, Viela Bio's trial on VIB7734 was finalized in June 2021 while Sanofi wrapped up their SAR443122 trial in April 2021. Eli Lilly and Company also completed a study on LY3471851 back in August 2020. These trials represent significant strides towards finding better therapies for SLE patients and highlight the ongoing commitment of various pharmaceutical companies to tackle this challenging autoimmune disease head-on.